UNSPSC 51286501: Mupirocin

This classification denotes a topical anti-infective agent with the molecular formula C26H44O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0GX863OA5, chemically known as 8-carboxyoctyl (e)-4-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2h-pyran-2-yl)-3-methylcrotonat but more generally known as mupirocin, which bears US NIH Compound Identifier 446596.

UNSPSC 51286501 Mupirocin is a Commodity code that nominally covers a single topical antibiotic product, but the state and local opportunities recently tagged under this code show little alignment with mupirocin procurement itself. Instead, the recent solicitations span a much broader range of pharmaceutical and medical supply categories — naloxone, over-the-counter products, generic multi-source pharmaceuticals, and emergency medical consumables — suggesting either miscoding in state and local procurement systems or use of the code as a catchall for pharmaceutical line-item procurement. The work being solicited includes purchase of finished pharmaceutical products and medical supplies for health agencies, fire departments, and pharmacy benefit programs, typically in high volumes with quarterly or annual delivery cycles, firm pricing, and strict compliance requirements including Drug Supply Chain Security Act certification, current Good Manufacturing Practices, and FDA approval.

Issuing bodies include state health agencies (Texas Health and Human Services Commission), counties (Seminole County, Florida), cities (Tampa Fire Department), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local members across multiple states including Oregon). Recent activity spans Texas, Florida, and Minnesota, with the Minnesota MMCAP cooperative notably serving a multi-state footprint. Representative opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the City of Tampa's IFB 26-P-00145 for medical and first aid supplies (estimated contract value $700,000.00) with a March 13, 2026 deadline; the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription capabilities with an April 3, 2026 response date; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline. The Tampa procurement includes a sheltered-market set-aside for certified Small Local Business Enterprises with a 5 percent bid discount, while other opportunities do not specify disadvantaged-enterprise designations.